Impact of non-proteinogenic amino acids in the discovery and development of peptide therapeutics

被引:0
作者
Yun Ding
Joey Paolo Ting
Jinsha Liu
Shams Al-Azzam
Priyanka Pandya
Sepideh Afshar
机构
[1] Eli Lilly and Company,Protein Engineering, Lilly Biotechnology Center
[2] Eurofins Lancaster Laboratories,Professional Scientific Services
来源
Amino Acids | 2020年 / 52卷
关键词
Non-proteinogenic amino acid; Peptide therapeutic; Discovery; Development;
D O I
暂无
中图分类号
学科分类号
摘要
With the development of modern chemistry and biology, non-proteinogenic amino acids (NPAAs) have become a powerful tool for developing peptide-based drug candidates. Drug-like properties of peptidic medicines, due to the smaller size and simpler structure compared to large proteins, can be changed fundamentally by introducing NPAAs in its sequence. While peptides composed of natural amino acids can be used as drug candidates, the majority have shown to be less stable in biological conditions. The impact of NPAA incorporation can be extremely beneficial in improving the stability, potency, permeability, and bioavailability of peptide-based therapies. Conversely, undesired effects such as toxicity or immunogenicity should also be considered. The impact of NPAAs in the development of peptide-based therapeutics is reviewed in this article. Further, numerous examples of peptides containing NPAAs are presented to highlight the ongoing development in peptide-based therapeutics.
引用
收藏
页码:1207 / 1226
页数:19
相关论文
共 1247 条
[1]  
Agerso H(2002)The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men Diabetologia 45 195-202
[2]  
Jensen LB(2017)Biocatalysis with unnatural amino acids: enzymology meets xenobiology Angew Chem Int Ed Engl 56 9680-9703
[3]  
Elbrond B(2005)Identification of novel targeting peptides for human ovarian cancer cells using “one-bead one-compound” combinatorial libraries Mol Cancer Ther 4 806-813
[4]  
Rolan P(1993)SDZ CO 611: a highly potent glycated analog of somatostatin with improved oral activity Life Sci 53 517-525
[5]  
Zdravkovic M(1992)A conformation of cyclosporin A in aqueous environment revealed by the X-ray structure of a cyclosporin-Fab complex Science 256 92-94
[6]  
Agostini F(2004)Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library Int J Cancer 111 165-173
[7]  
Voller JS(2018)A review of GLP-1 receptor agonists: evolution and advancement, through the lens of randomised controlled trials Diabetes Obes Metab 20 22-33
[8]  
Koksch B(2018)Immunosilencing peptides by stereochemical inversion and sequence reversal: retro-D-peptides Sci Rep 8 6446-7630
[9]  
Acevedo-Rocha CG(2000)Hydration changes implicated in the remarkable temperature-dependent membrane permeation of cyclosporin A Biochemistry 39 7621-2457
[10]  
Kubyshkin V(2007)Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide J Am Chem Soc 129 2456-2599